Healthy adult volunteers were 1:1 randomized to receive either intranasally LAIV (2015/2016 Fluenz Tetra or FluMist Tetra, AstraZeneca, UK) or intramuscular Quadrivalent Inactivated Influenza Vaccination (Fluarix Tetra, GlaxoSmithKline, UK) as described previously 14 (link). The control group also received a nasal saline spray, while the LAIV group also received a intramuscular saline injection. Three days post vaccination all subjects were inoculated with 80,000 CFU per nostril of 6B type Spn as described 6 (link),51 (link). Nasal microbiopsies (ASL Rhino-Pro©, Arlington Scientific) and nasal lining fluid (Nasosorption™, Hunt Developments) samples were collected and stored at -80C as previously described 52 (link).